LiquiMAX Alkaline Phosphatase Mono (DGKC Method / DEA Buffer)

Alkaline phosphatase in serum consists of four structural genotypes: the liverbone-kidney type, the intestinal type, the placental type and the variant from germ cells. It occurs in osteoblasts, hepatocytes, kidneys, spleen, placenta, prostate, leukocytes and the small intestine. The liverbone-kidney type is particularly important. A rise in the Alkaline Phosphatase activity occurs with all forms of cholestasis, particularly with obstructive jaundice. It is also elevated in diseases of the skeletal system, such as Paget`s disease, hyperparathyroidism, rickets and osteomalacia, as well as with fractures and malignant tumors. A considerable rise in the Alkaline Phosphatase activity is sometimes seen in children and juveniles. It is caused by increased osteoblast activity following accelerated bone growth. Various reference values for the purposes of clinical evaluation have been assigned to differing age groups. In 1946, Bessey, Lowry and Brock published a method for the determination of Alkaline Phosphatase using p-nitrophenyl phosphate as substrate buffered with glycine/NaOH. in 1967, Hausamen et al improved upon the method by using Diethanolamine as buffer. The “optimized standard method” assay described here meets the 1972 recommendations of the “Deutschen Gesellschaft für Klinische Chemie (German Society of Clinical Chemistry)